Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

insulin aspart (Rx)Brand and Other Names:NovoLog, NovoLog FlexPen, more...NovoPen Echo, NovoLog FlexTouch

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 100 units/mL

prefilled syringe

  • 100units/mL (3mL NovoLog FlexPen or FlexTouch)
more...

Type 1 Diabetes Mellitus

Improvement of glycemic control in adults and children with diabetes mellitus

May administer 0.2-0.6 unit/kg/day in divided doses; conservative doses of 0.2-0.4 unit/kg/day often recommended to reduce risk of hypoglycemia

Total maintenance daily insulin requirement may vary; it is usually between 0.5 and 1 unit/kg/day; nonobese may require 0.4-0.6 unit/kg/day; obese may require 0.6-1.2 units/kg/day

Type 2 Diabetes Mellitus

Diabetes inadequately controlled by diet, weight reduction, exercise, or oral medication

10 units/day SC (or 0.1-0.2 units/kg/day) in evening or divided q12hr of an intermediate (eg, NPH) or long-acting insulin at bedtime recommended; conversely, regular insulin or rapid-acting insulin (aspart insulin) before meals also recommended

Dosing Considerations

When used in a meal-related SC injection treatment regimen, 50-75% of total insulin requirements may be provided by an intermediate-acting or long-acting insulin; the remainder is divided and provided before or at mealtimes as a rapid-acting insulin, such as insulin aspart

Because of insulin aspart’s comparatively rapid onset and short duration of glucose-lowering activity, some patients may require more basal insulin and more total insulin to prevent premeal hyperglycemia than they would need when using human regular insulin

Dosage must be individualized; blood and urine glucose monitoring is essential in all patients receiving insulin therapy

Insulin requirements may be altered during stress or major illness or with changes in exercise, meal patterns, or coadministered drugs

SC injection

  • Administer within 5-10 minutes before a meal
  • When administered by SC injection, insulin aspart should generally be used in regimens with an intermediate- or long-acting insulin
  • Injection sites should be rotated within the same region to reduce the risk of lipodystrophy
  • As with all insulins, the duration of action will vary according to the dose, injection site, blood flow, temperature, and level of physical activity

Continuous SC injection (insulin pump)

  • Divide the number of units by 24 to obtain the basal rate in units/hr
  • Change the NovoLog in the reservoir at least every 6 days
  • Change the infusion set and the infusion set insertion site at least every 3 days
  • Do not mix with other insulins or with a diluent when it is used in the pump

IV administration

  • IV use is at concentrations of 0.05-1 unit/mL in infusion systems using PVC infusion bags
  • Stable in infusion fluids such as 0.9% NaCl

Dosage Forms & Strengths

injectable solution

  • 100 units/mL

prefilled syringe

  • 100units/mL (3mL NovoLog FlexPen or FlexTouch)
more...

Type 1 Diabetes Mellitus

Improvement of glycemic control in adults and children with diabetes mellitus

>2 years: May require 0.8-1.2 units/kg/day SC during growth spurts; adolescents may require ≤1.2 units/kg/day; otherwise, may use 0.5-1 unit/kg/day

Dosing considerations

  • Insulin pens specifically designed for children and adolescents allow for 0.5 unit dosage increments (eg, NovoPen Echo, NovoPen Junior)
  • Dosage of human insulin, which is always expressed in USP units, must be based on the results of blood and urine glucose tests and must be carefully individualized to optimal effect
  • NovoLog approved for children >2 years for SC daily injections and for children >4 years for continuous SC infusion
  • 50-75% of daily insulin requirement may be supplied by intermediate- to long-acting insulin; the remainder is divided and provided before or at mealtimes as a rapid-acting insulin, such as insulin aspart
Next

Interactions

Interaction Checker

insulin aspart and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency Not Defined

            Hypoglycemia

            Lipodystrophy

            Lipohypertrophy

            Local allergic reaction

            Hypokalemia

            Paresthesia

            Itching

            Tremor

            Hunger

            Nausea

            Urticaria

            Redness

            Diaphoresis

            Hypothermia

            Mental confusion

            Loss of consciousness

            Muscle weakness

            Previous
            Next

            Warnings

            Contraindications

            During episodes of hypoglycemia

            Documented hypersensitivity

            Cautions

            Decreased insulin requirements: Diarrhea, nausea/vomiting, malabsorption, hypothyroidism, renal impairment, and hepatic impairment

            Increased insulin requirements: Fever, hyperthyroidism, trauma, infection, and surgery

            Hypoglycemia is the most common adverse reaction

            May cause a shift in potassium from extracellular to intracellular space, possibly leading to hypokalemia; caution when coadministered with potassium-lowering drugs or in conditions that may decrease potassium

            Frequent glucose monitoring and insulin dose reduction may be required with renal or hepatic impairment

            Do not mix SC injection with insulin preparations other than NPH insulin

            Do not mix IV or continuous SC infusions with any other insulins

            Pregnancy

            Thiazolidinediones are peroxisome proliferator-activated receptor (PPAR)-gamma agonists and can cause dose-related fluid retention, particularly when used in combination with insulin; fluid retention may lead to or exacerbate heart failure; monitor for signs and symptoms of heart failure, treat accordingly, and consider discontinuing thiazolidinediones

            Never share pen between patients even if needle is changed

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: B; Open-label, randomized trial (n=322) observed insulin aspart reduced Hgb A1C similarly to regular insulin in pregnant women

            Lactation: Considered safe for use while breastfeeding

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Regulates glucose metabolism

            Insulin and its analogues lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production; insulin inhibits lipolysis and proteolysis, and enhances protein synthesis; targets include skeletal muscle, liver, and adipose tissue

            Absorption

            Bioavailability: SC, well absorbed (2-3 times faster than regular insulin)

            Onset: 0.2-0.3 hr; 1-3 hr (peak effect)

            Duration of action: 3-5 hr

            Peak plasma time: 40-50 minutes

            Peak plasma concentration: 82 microunits/L

            Distribution

            Protein bound: <10%, similar to regular insulin (not bound to serum binding-protein, but present as a monomer in plasma)

            Vd: 0.26-0.36 L/kg

            Metabolism

            Liver (>50%); kidney (30%); adipose tissue/muscle (20%)

            Elimination

            Half-life: 81 min (SC)

            Excretion: Urine

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.